Project Grant R21DA060522
Award Date
6/15/25
Completion Date
5/31/27
Dollars Obligated
$406K
Federal Agency
National Institute on Drug Abuse
Federal Grant Program
93.279
Assistance Type
Project Grant
Place of Performance
Eugene, OR 97403, USA
Similar Awards
This federal Project Grant award, provided by the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279), will fund research to examine the effects of psilocybin on brain function, cognition, and behavior in individuals with opioid use disorder (OUD). The $1,462,135 award will support a two-phase study over a 24-month period starting on Jul 1, 2024. In the initial R61 phase, the study will prospectively assign 72 OUD participants to receive...
The National Institute on Drug Abuse (NIDA) awarded a 5-year, $445,500 Project Grant under the Drug Use and Addiction Research Programs (CFDA 93.279) to the University of Alabama at Birmingham (UAB). The grant aims to use the nematode worm Caenorhabditis elegans as a model system to conduct high-throughput screening and characterization of genetic regulators underlying drug-induced neuroplasticity and substance use disorder. By generating comprehensive molecular, behavioral, and neuronal...
The federal Project Grant award F99NS139512, with $130,722.00 in funding, was provided by the National Institutes of Health (NIH) Office of the Director under the Trans-NIH Research Support program (CFDA 93.310). The grant supports research at The Washington University in St. Louis to investigate the effects of psychedelics on brain function and neuroplasticity. Specifically, the research aims to determine whether short-duration versus long-duration psychedelics differentially impact...
This Project Grant award from the National Institute on Drug Abuse (CFDA 93.279 - Drug Use and Addiction Research Programs) provides $421,200.00 to Oregon Health & Science University to develop innovative chemical biology tools for studying the role of cannabinoid receptors in opioid use disorder. The key objectives are to expand the university's existing toolkit of fluorescent probes and photoswitches that can be used to precisely monitor and manipulate cannabinoid receptor signaling,...
This Project Grant award from the National Institute of Mental Health (NIMH) under the Mental Health Research Grants program (CFDA 93.242) aims to investigate the role of cortical GABAergic interneurons in the effects of the psychedelic drug psilocybin. The $627,945 award to Cornell University will fund a 5-year study to determine how psilocybin administration affects the activity of the three major subtypes of GABAergic interneurons in the mouse medial frontal cortex. The researchers will use...
This Project Grant award from the National Institute of Mental Health (NIMH), under the Mental Health Research Grants program (CFDA 93.242), provides $237,000 to the University of California, San Diego (UCSD) to develop translational depression-relevant models in mice. The goal is to better evaluate the efficacy of psychedelic agents, such as psilocybin, in reversing depression-relevant amotivated behaviors and identifying associated electroencephalographic (EEG) biomarkers. Specifically, the...
This Project Grant award from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), will support research to map molecular changes in the habenula brain region associated with chronic opioid exposure. The $284,040 grant will be used to conduct integrated single-cell and spatial transcriptomic analyses in rodents to identify projection-specific molecular pathways impacted by opioid use disorder. The research aims to generate a comprehensive...
The National Institute on Drug Abuse (NIDA) awarded a $1,039,420 Project Grant (CFDA 93.279 - Drug Use and Addiction Research Programs) to the Medical University of South Carolina (MUSC) to conduct research on the neural circuits underlying the facilitation and disinhibition of opioid and alcohol seeking behaviors. The project will use innovative tools like single-nucleus RNA sequencing, spatial sequencing, in vivo calcium imaging, and holographic optogenetics to characterize the...
This Project Grant award, funded by the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279), aims to advance the understanding of the role of the epigenetic regulators G9A and GLP in the development of addictive behaviors. The $272,395 award, with a period of performance from April 15, 2025 to March 31, 2027, will support research conducted by The Regents of the University of California, San Francisco (UCSF) to: Identify molecular surfaces...
This Project Grant award of $772,800 was provided by the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279). The primary objective is to identify and pharmacologically target novel modulators of the mu-opioid receptor (MOR) signaling to dissociate the beneficial analgesic effects of opioids from the development of dependence, tolerance, and other undesirable side effects. The research approach involves using large-scale, unbiased screening...